INT32569

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 1980
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 18
Total Number 18
Disease Relevance 2.46
Pain Relevance 4.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (GGH) extracellular space (GGH) extracellular region (GGH)
lysosome (GGH)
Anatomy Link Frequency
plasma 1
urine 1
GGH (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 9 99.88 Very High Very High Very High
GABAergic 6 99.78 Very High Very High Very High
opiate 2 99.60 Very High Very High Very High
Clonidine 13 99.58 Very High Very High Very High
Opioid 7 99.32 Very High Very High Very High
antagonist 6 99.12 Very High Very High Very High
gABA 3 98.52 Very High Very High Very High
narcan 16 98.42 Very High Very High Very High
dopamine receptor 1 98.04 Very High Very High Very High
Sumatriptan 15 97.98 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pain 9 99.88 Very High Very High Very High
Obesity 31 99.84 Very High Very High Very High
Aging 3 99.36 Very High Very High Very High
Mental Disorders 20 97.88 Very High Very High Very High
Cv Unclassified Under Development 1 97.76 Very High Very High Very High
Natriuresis 2 90.80 High High
Syndrome 1 82.08 Quite High
Chronic Disease 11 5.00 Very Low Very Low Very Low
Disease 3 5.00 Very Low Very Low Very Low
Pulmonary Disease 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The evaluation of a possible interaction between opioid peptides and GABAergic system on GH release requires further investigation.
Localization (release) of GH associated with gabaergic and opioid
1) Confidence 0.80 Published 1983 Journal J. Endocrinol. Invest. Section Abstract Doc Link 6319478 Disease Relevance 0 Pain Relevance 0.43
To evaluate the interaction between opioid peptides and GABAergic system in regulating GH secretion we administered 5 mg of baclofen, a GABA derivative, to eight normal male subjects.
Localization (secretion) of GH associated with gaba, gabaergic and opioid
2) Confidence 0.80 Published 1983 Journal J. Endocrinol. Invest. Section Abstract Doc Link 6319478 Disease Relevance 0 Pain Relevance 0.41
Naloxone does not alter the effect of gamma aminobutyric acid derivative, baclofen, on GH release in man.
Localization (release) of GH associated with narcan
3) Confidence 0.80 Published 1983 Journal J. Endocrinol. Invest. Section Title Doc Link 6319478 Disease Relevance 0 Pain Relevance 0.49
Sumatriptan induced a striking increase in plasma GH levels in the younger group, whereas it slightly increased GH secretion in the older group (f = 9.59, p < 0.02).
Localization (secretion) of GH in plasma associated with sumatriptan
4) Confidence 0.75 Published 1995 Journal J. Neural Transm. Gen. Sect. Section Abstract Doc Link 8695049 Disease Relevance 0.08 Pain Relevance 0.47
The present study was undertaken in order to assess the influence of aging on the serotonergic control of GH secretion in humans.
Localization (secretion) of GH associated with aging
5) Confidence 0.75 Published 1995 Journal J. Neural Transm. Gen. Sect. Section Abstract Doc Link 8695049 Disease Relevance 0.10 Pain Relevance 0.36
These data show impaired serotonergic stimulatory regulation of GH secretion in elderly subjects.
Localization (secretion) of GH
6) Confidence 0.75 Published 1995 Journal J. Neural Transm. Gen. Sect. Section Abstract Doc Link 8695049 Disease Relevance 0.07 Pain Relevance 0.45
CONCLUSIONS: These results indicate that clonidine and l-dopa stimulate GH secretion mainly through the release of hypothalamic GHRH, and that arginine- and insulin-induced hypoglycaemia stimulate GH secretion mainly through the inhibition of hypothalamic somatostatin release.
Localization (secretion) of GH
7) Confidence 0.47 Published 2002 Journal Eur. J. Endocrinol. Section Body Doc Link 11834428 Disease Relevance 0 Pain Relevance 0
CONCLUSIONS: These results indicate that clonidine and l-dopa stimulate GH secretion mainly through the release of hypothalamic GHRH, and that arginine- and insulin-induced hypoglycaemia stimulate GH secretion mainly through the inhibition of hypothalamic somatostatin release.
Localization (secretion) of GH
8) Confidence 0.47 Published 2002 Journal Eur. J. Endocrinol. Section Body Doc Link 11834428 Disease Relevance 0 Pain Relevance 0
RESULTS: The combined administration of GHRH-Ant distinctly inhibited the arginine- and insulin-induced GH release.
Localization (release) of GH
9) Confidence 0.47 Published 2002 Journal Eur. J. Endocrinol. Section Body Doc Link 11834428 Disease Relevance 0 Pain Relevance 0
OBJECTIVE: The role of endogenous GHRH in arginine-, insulin-, clonidine- and l-dopa-induced GH secretion was studied in man using a GHRH antagonist (GHRH-Ant).
Localization (secretion) of GH associated with antagonist and clonidine
10) Confidence 0.47 Published 2002 Journal Eur. J. Endocrinol. Section Abstract Doc Link 11834428 Disease Relevance 0 Pain Relevance 0.22
However, the presence of endogenous hypothalamic GHRH seems to be essential for the maximal stimulation of GH release induced by arginine and insulin.


Localization (release) of GH
11) Confidence 0.47 Published 2002 Journal Eur. J. Endocrinol. Section Body Doc Link 11834428 Disease Relevance 0 Pain Relevance 0
The role of endogenous GHRH in arginine-, insulin-, clonidine- and l-dopa-induced GH release in normal subjects.
Localization (release) of GH associated with clonidine
12) Confidence 0.47 Published 2002 Journal Eur. J. Endocrinol. Section Title Doc Link 11834428 Disease Relevance 0 Pain Relevance 0.24
It was evident that the PF, RP, BP, and GH dimensions were correlated with PCS, while the VT, SF, RE, and MH dimensions were correlated with MCS.
Localization (dimensions) of GH associated with mental disorders and pain
13) Confidence 0.39 Published 2008 Journal BMC Public Health Section Body Doc Link PMC2527564 Disease Relevance 0.67 Pain Relevance 0.27
Preliminary results point to a clear potentiation of GH release when the opiate receptor blockade is added to a dopamine receptor stimulation.
Localization (release) of GH associated with dopamine receptor and opiate
14) Confidence 0.35 Published 1980 Journal Boll. Soc. Ital. Biol. Sper. Section Abstract Doc Link 6257257 Disease Relevance 0 Pain Relevance 0.23
Our results argue against the hypothesis of an enhanced SRIH tone as the cause of impaired GH secretion in obese patients, a primary defect in GHRH or GH release seems more likely.
Localization (secretion) of GH associated with obesity
15) Confidence 0.27 Published 1995 Journal Int. J. Obes. Relat. Metab. Disord. Section Abstract Doc Link 7719386 Disease Relevance 0.61 Pain Relevance 0.09
Our results argue against the hypothesis of an enhanced SRIH tone as the cause of impaired GH secretion in obese patients, a primary defect in GHRH or GH release seems more likely.
Localization (release) of GH associated with obesity
16) Confidence 0.27 Published 1995 Journal Int. J. Obes. Relat. Metab. Disord. Section Abstract Doc Link 7719386 Disease Relevance 0.59 Pain Relevance 0.09
Both analogues, when injected i.v. at a dose of 100 micrograms, stimulated release of prolactin and GH and inhibited serum cortisol; there was no significant change in blood pressure, pulse rate or urine output.
Localization (release) of GH in urine associated with cv unclassified under development
17) Confidence 0.21 Published 1988 Journal J. Endocrinol. Section Abstract Doc Link 2965206 Disease Relevance 0.26 Pain Relevance 0.35
An increase in endogenous GH secretion or a direct hepatic effect have been suggested as possible mechanisms.
Localization (secretion) of GH
18) Confidence 0.17 Published 2001 Journal J. Endocrinol. Invest. Section Abstract Doc Link 11817711 Disease Relevance 0.08 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox